Recall Ledger

MYXREDLIN recall (Baxter Healthcare Corporation)

DrugClass IIOngoing

Summary: Baxter Healthcare Corporation is recalling MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.. Reason: CGMP Deviations.

What is being recalled

MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.

Why

CGMP Deviations

How serious is it

Class II is the middle level: using or being exposed to this product may cause temporary or medically reversible health problems, and the chance of serious harm is remote.

Where it was sold

US Nationwide; Puerto Rico; and Chile. (states named: Puerto Rico)

How to tell if yours is affected

Lot # NC188630, NC188708, NC188791, NC188845, NC188876, NC188968, Exp Date: 12/31/2027; Lot # NC193719, NC193849, Exp Date: 04/30/2028; Lot # NC194051, NC194105, Exp Date: 05/31/2028; Lot # NC195171, Exp Date: 06/30/2028.

What to do

Check the product name, lot number and expiration date on your package against the codes above. If they match, do not stop taking a prescription medicine without talking to your doctor or pharmacist first; ask them about a replacement. Return or dispose of the product as your pharmacy advises.

Recall facts

Recall numberD-0806-2026
CategoryDrug
AgencyU.S. Food and Drug Administration (FDA)
SeverityClass II
StatusOngoing
Recall startedAugust 6, 2026
ReportedSeptember 9, 2026
CompanyBaxter Healthcare Corporation
Company locationDeerfield, IL, United States
Initiated byVoluntary: Firm initiated
QuantityN/A

More recalls from Baxter Healthcare Corporation · all drug recalls · recalls from August 2026

Official FDA record